Brokerages expect TherapeuticsMD Inc (NASDAQ:TXMD) to post ($0.19) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for TherapeuticsMD’s earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.17). TherapeuticsMD posted earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year over year growth rate of 18.8%. The business is expected to announce its next quarterly earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that TherapeuticsMD will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.68). For the next year, analysts forecast that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.63) to $0.05. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). The company had revenue of $6.08 million during the quarter, compared to analysts’ expectations of $5.12 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. TherapeuticsMD’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.15) earnings per share.
Several equities analysts have recently weighed in on the company. Cowen reduced their price target on TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Noble Financial reiterated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Monday, August 12th. JPMorgan Chase & Co. reduced their price target on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Wednesday, August 7th. Finally, ValuEngine upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $9.28.
In other TherapeuticsMD news, CEO Robert G. Finizio bought 35,000 shares of TherapeuticsMD stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average cost of $2.74 per share, for a total transaction of $95,900.00. Following the completion of the transaction, the chief executive officer now directly owns 18,253,964 shares in the company, valued at $50,015,861.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C.K. Iv Milligan bought 15,000 shares of TherapeuticsMD stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $3.16 per share, with a total value of $47,400.00. Following the completion of the transaction, the insider now owns 1,472,419 shares of the company’s stock, valued at $4,652,844.04. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 160,549 shares of company stock valued at $465,467. 18.91% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Moors & Cabot Inc. purchased a new position in TherapeuticsMD during the second quarter worth about $25,000. Moloney Securities Asset Management LLC bought a new stake in TherapeuticsMD during the second quarter worth about $27,000. Highland Private Wealth Management bought a new stake in TherapeuticsMD during the second quarter worth about $28,000. H D Vest Advisory Services bought a new stake in TherapeuticsMD during the second quarter worth about $34,000. Finally, Advisor Group Inc. lifted its stake in TherapeuticsMD by 73.2% during the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock worth $36,000 after purchasing an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.
Shares of NASDAQ TXMD traded down $0.02 during mid-day trading on Friday, hitting $2.76. The company had a trading volume of 30,496 shares, compared to its average volume of 3,921,834. The company has a market capitalization of $658.53 million, a price-to-earnings ratio of -4.65 and a beta of 1.90. TherapeuticsMD has a 1 year low of $1.82 and a 1 year high of $6.94. The company has a current ratio of 5.17, a quick ratio of 4.99 and a debt-to-equity ratio of 24.29. The stock’s 50-day moving average price is $2.49 and its 200-day moving average price is $3.85.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Read More: What is the strike price in options trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.